SIOPEN STATEMENTS
Position statement on the use of DFMO
We would like to share with you an updated version of the DFMO position statement.
This update reflects an evolving and complex landscape across Europe, where access to DFMO remains heterogeneous and continues to pose significant challenges. SIOPEN remains committed to supporting equitable access, generating robust clinical evidence, and working collaboratively to improve the situation for patients across Europe.
We believe that SIOPEN should have a common position regarding DFMO, which will start to be available for some countries (Switzerland, the UK, and Australia) on Monday, Oct 7th, 2024. We understand that the Expanded Access Program providing the drug at no cost will open in other EU countries during 2025.
We hope that this statement, prepared with the Executive Committee and feedback from our Advocate Committee includes our perspective on the current situation and, of course, will modify it depending on the circumstances, particularly regulatory decision.
We also realise that the different access situations across our network will generate considerable challenges over the next months/years and hope to work to minimise them by including them in HRNBL2 trial.